AXGN

AxoGen is expected to report Q3 2026 earnings of $0.14 per share with 21.2% revenue growth on October 28, but carries a 0% Earnings ESP with a Zacks Rank #2, making it difficult to predict an earnings beat. Meanwhile, IQVIA is projected to post $3.24 EPS with 6.4% revenue growth, but faces a negative Earnings ESP of -0.09% combined with a Zacks Rank #4 (Sell), suggesting limited upside potential despite a history of beating estimates.

In a comparison of two medical instruments stocks, Globus Medical (GMED) and AxoGen (AXGN), both holding a Zacks Rank #2 (Buy), GMED emerges as the superior value option. GMED has a forward P/E of 15.81 compared to AXGN's 73.46, a PEG ratio of 1.27 vs 1.42, and a P/B ratio of 2.22 vs 7.47, earning GMED a Value grade of B while AXGN received an F.

AxoGen (AXGN) has declined 22.6% over four weeks and is now in oversold territory with an RSI reading of 27.04, suggesting a potential reversal. Wall Street analysts have raised earnings estimates by 2.2% over the past 30 days, and the stock holds a Zacks Rank #2 (Buy) rating, indicating potential for near-term price appreciation.

DexCom (DXCM) reported strong Q2 2026 results with gross margin expanding to 64.1% and operating margin at 25.1%, driven by manufacturing efficiencies and G7 15-day product transition. However, near-term profitability could face pressure from Ireland factory ramp-up costs, forex headwinds, and higher oil-linked input costs. The company maintains a Zacks Rank #3 (Hold) rating with shares up 29.4% year-to-date.